PRLD Research | Milton Maxwell

PRLD

Prelude Therapeutics Incorporated

1.9900

+0.0500+2.58%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

125.10M

P/E (TTM)

Basic EPS (TTM)

-1.47

Dividend Yield

Recent Filings

8-K

ATM prospectus supplement filed

3/12/26Mar 12, 2026

Prelude Therapeutics filed a prospectus supplement on March 12, 2026, enabling up to $25.0 million in common stock sales under its existing $75.0 million Sales Agreement with Jefferies. This activates part of the at-the-market offering for potential capital raise. No sales have occurred yet.

10-K

FY2025 results

3/10/26Mar 10, 2026

Prelude Therapeutics narrowed FY2025 net loss to $99.5M from $127.2M in FY2024, driven by $23.7M R&D cuts after pausing SMARCA2 degrader clinical work and workforce reductions, while revenue jumped to $12.1M from $7.0M via Incyte option and AbCellera deals. Q4 momentum built with $60M Incyte cash ($35M upfront + $25M equity) for JAK2V617F program option, yielding $2.6M revenue recognition; cash hit $106.4M, funding ops to Q2 2027. R&D fell to $94.3M (PRT3789 $13.5M, discovery $12.1M), G&A to $22.4M. Pipeline advances KAT6A IND mid-2026. Clinical trial delays risk momentum.

8-K

Prelude's 2025 results, pipeline advances

3/10/26Mar 10, 2026

Prelude Therapeutics reported 2025 results with net loss shrinking to $99.5M from $127.2M, R&D expenses dropping to $94.3M, and $106.4M cash funding operations into Q2 2027. FDA cleared IND for PRT12396 JAK2 inhibitor; Phase 1 starts Q2 2026 in PV and MF. KAT6A degrader PRT13722 IND mid-2026. Cash lasts through key catalysts.

8-K

FDA clears PRT12396 IND

2/3/26Feb 3, 2026

Prelude Therapeutics secured FDA clearance for its IND on PRT12396, a mutant-selective JAK2V617F inhibitor targeting polycythemia vera and myelofibrosis in MPN patients. Phase 1 dosing starts by Q2 2026. FDA greenlight advances JAK2 program under Incyte option. Clinical risks loom large.

8-K

Pipeline advances JAK2, KAT6A

1/9/26Jan 9, 2026

Prelude Therapeutics unveiled its January 2026 investor presentation, spotlighting preclinical progress on JAK2V617F mutant-selective inhibitors for MPNs and first-in-class KAT6A degraders for ER+ breast cancer. Phase 1 for JAK2V617F starts 2Q 2026 under Incyte option; KAT6A IND mid-2026. Cash lasts to Q2 2027. Programs target validated markets.

About

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

CEO

Dr. Krishna Vaddi D.V.M., Ph.D.

IPO

9/25/2020

Website

https://preludetx.com

Employees

131

Sector

Healthcare

Industry

Biotechnology